---
title: "Ping An Biomedical Calls March 18 AGM to Approve Dual-Class Shares and Major Share Consolidation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278423288.md"
description: "Ping An Biomedical has announced its annual general meeting on March 18, 2026, in Hong Kong, where shareholders will vote on significant changes to the company's capital structure. The proposals include creating dual-class shares, expanding authorized capital to 5 billion ordinary shares, and implementing a major share consolidation. These changes aim to enhance voting power concentration and align corporate governance. If approved, this will mark a shift towards a dual-class structure, potentially tightening control and managing share count for its U.S.-listed equity."
datetime: "2026-03-09T16:27:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278423288.md)
  - [en](https://longbridge.com/en/news/278423288.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278423288.md)
---

# Ping An Biomedical Calls March 18 AGM to Approve Dual-Class Shares and Major Share Consolidation

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Ping An Biomedical ( (PASW) ) has shared an update.

Ping An Biomedical on March 9, 2026, notified shareholders that its annual general meeting will be held on March 18, 2026, in Hong Kong, with shareholders of record as of March 3 entitled to vote. The agenda centers on reshaping the capital structure through the creation of dual-class shares, extensive authorized capital expansion, and related constitutional changes.

The company is seeking approval to increase its authorized capital to 5 billion ordinary shares while reclassifying most of them into Class A stock and introducing a new Class B class carrying 100 votes per share, which would enhance voting power concentration. It is also proposing adoption of a second amended and restated memorandum and articles of association, a share repurchase and matching issuance of Class B shares to INSPIRETECH LTD, and a large share consolidation to reduce the number of outstanding shares and align corporate documents accordingly.

These measures, if approved on March 18, would significantly alter Ping An Biomedical’s governance and share structure by formalizing a high-vote share class and enabling post-meeting consolidation of both A and B shares. For existing investors, the package signals a move toward a dual-class structure and potential tightening of control, while using consolidation to manage share count and possibly address trading dynamics in its U.S.-listed equity.

**More about Ping An Biomedical**

Ping An Biomedical Co., Ltd. is a Cayman Islands–incorporated biomedical company with principal executive offices in Hong Kong. The company’s shares are listed in the United States as a foreign private issuer and it reports under Form 20-F, indicating an investor base that includes U.S. public market shareholders.

**Average Trading Volume:** 3,840,469

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $3.62M

For an in-depth examination of PASW stock, go to TipRanks’ Overview page.

### Related Stocks

- [PASW.US](https://longbridge.com/en/quote/PASW.US.md)

## Related News & Research

- [TGT Stock Alert: What to Know as Target Taps Former Walmart Exec](https://longbridge.com/en/news/286957668.md)
- [A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data](https://longbridge.com/en/news/286722721.md)
- [Should you invest $1,000 in AGNC Investment right now?](https://longbridge.com/en/news/286802595.md)
- [Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares](https://longbridge.com/en/news/286950631.md)
- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)